Labiana Health

Labiana Health Debt Growth

The Year-over-Year Debt Growth of Labiana Health (LAB.MC) as of Nov 19, 2026 is 10.85 %. In the previous year, Year-over-Year Debt Growth was -9.40 % — a change of -215.33% (higher).

Debt Growth

10.85 %

YoY

-215.33%

Last updated:

Year-over-Year Debt Growth of Labiana Health is 2025 10.85 % . Year-over-Year Debt Growth of Labiana Health was 2024 -9.40 % . It decreases by -215.33% higher compared to the previous year.

The Labiana Health Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2019
153.12 EUR
Jan 1, 2022
-39.14 EUR
Jan 1, 2023
107.58 EUR
Jan 1, 2024
-9.40 EUR
Jan 1, 2025
10.85 EUR
The Labiana Health Debt Growth history
YEARDebt GrowthYoY
10.85 %-215.33%
-9.40 %-108.74%
107.58 %-374.84%
-39.14 %-125.56%
153.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Year-over-Year Debt Growth of Labiana Health is 10.85 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Labiana Health

All Key Metrics — Labiana Health